Wolverine Trading
RXRX icon

Wolverine Trading’s Recursion Pharmaceuticals RXRX Stock Holding History

Wolverine Trading’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$715K Buy
145,600
+33,800
+30% +$178K ﹤0.01% 3278
2025
Q2 		$562K Buy
111,800
+7,200
+7% +$35.4K ﹤0.01% 2849
2025
Q1 		$608K Sell
104,600
-66,900
-39% -$488K ﹤0.01% 2757
2024
Q4 		$1.16M Buy
171,500
+10,300
+6% +$69.3K ﹤0.01% 2515
2024
Q3 		$1.13M Buy
161,200
+77,000
+91% +$552K ﹤0.01% 2236
2024
Q2 		$632K Buy
84,200
+11,300
+16% +$98.6K ﹤0.01% 2615
2024
Q1 		$727K Buy
72,900
+42,800
+142% +$477K ﹤0.01% 2493
2023
Q4 		$297K Buy
30,100
+12,900
+75% +$92K ﹤0.01% 3481
2023
Q3 		$132K Buy
+17,200
New +$172K ﹤0.01% 3910

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's RXRX Position: Q3 2025 in Review

Wolverine Trading increased its Recursion Pharmaceuticals (RXRX) stake by 26% in Q3 2025, buying an estimated $78.5K and bringing the position to 72,233 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #4135.

Wolverine Trading first reported a position in RXRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $598K in Q1 2025. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Wolverine Trading held 72,233 shares of Recursion Pharmaceuticals worth $355K as of Q3 2025.
  • Wolverine Trading bought 14,954 Recursion Pharmaceuticals shares in Q3 2025, an estimated $78.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4135 holding.
  • Wolverine Trading first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Wolverine Trading's Recursion Pharmaceuticals position peaked at $598K in Q1 2025.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.